Uncategorized

[International Immunopharmacology] Scientists reported the discovery of QP6126, a small-molecule glutaminyl-peptide cyclotransferase-like protein (QPCTL) inhibitor. QP6126 ablates the pGlu-CD47 modification, thereby abolishing CD47-SIRPα interaction, and sensitizing melanoma cells to macrophage-mediated phagocytosis.

[Advanced Materials] The authors provide an overview of piezoelectric biomaterials for skin wound healing and examine the physiological and biochemical roles of the naturally occurring electric fields in healthy skin and injured skin.

[Cell Death & Disease] Using transcriptome analysis of more than 15,000 RNA-seq samples across 54 human tissues, scientists identified terminal epidermal differentiation-associated RNA (TEDAR), a highly skin-enriched lncRNA.

[Communications Biology] Investigators showed that Alkbh5 expression is downregulated during late telogen, and its deletion promotes hair follicle stem cell activation and proliferation, accelerating the telogen–anagen transition in mice.

[JCI Insight] Researchers identified GLS1-mediated glutaminolysis as a metabolic program preferentially induced in keratinocytes under type 3 inflammatory conditions. Integrated transcriptomic, metabolomic, genetic, and functional analyses showed that IL-17A induced GLS1 expression and glutaminolysis in keratinocytes.

[JCI Insight] Investigators employed multiomics profiling of clinical samples to investigate metabolic alterations during wound healing. They developed a transdermal microneedle platform based on gelatin methacryloyl for localized αKG delivery, further accelerating tissue repair.

[Scientific Reports] Researchers established an epidermal stress model was established using cortisol-stimulated human keratinocytes to systematically evaluate the cytoprotective effects of Taikong Blue lavender essential oil .

[Immunocore ] Immunocore announced the achievement of target patient enrollment in the TEBE-AM clinical trial, a randomized, registrational Phase III clinical trial evaluating KIMMTRAK as monotherapy and in combination with pembrolizumab for the treatment of HLA-A*02:01-positive patients with advanced melanoma.

[Nature Communications] Researchers developed a monoclonal antibody targeting myelin protein zero–like 1 (MPZL1)’s extracellular domain and engineered CAR-T cells that selectively eliminate MPZL1-positive cancer cells in vitro.

[Critical Reviews in Oncology/Hematology] The authors provide an overview of the key physiological barriers encountered in in vivo CAR-T cell engineering, alongside the corresponding principles of engineered design.

[Blood Advances] This multicenter, single-arm, Phase I/II study evaluated the safety and efficacy of CD19-directed allogeneic CAR immunotherapy CTX110 in adult patients with relapsed/refractory B cell non-Hodgkin lymphoma.

[Cancer Immunology Research] In this first-in-human, open-label, Phase I, dose-escalation study, researchers evaluated a single TAK-102 infusion in 11 patients with glypican-3-positive advanced solid tumors refractory or intolerant to standard therapies.